Evidence map›Paper›PMID 27833387›Full record

ArticleWorld journal of gastroenterology2016

Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification.

Deepak Kalyansingh Burad, Thomas Alex Kodiatte, Sayd Mohamed Rajeeb, Ashish Goel, Chundamannil Eapen Eapen, Banumathi Ramakrishna

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Primary hepatic neuroendocrine tumor: A case report and literature review.International journal of surgery case reports · 2020
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Deepak Kalyansingh BuradDeepak Kalyansingh Burad, Thomas Alex Kodiatte, Banumathi Ramakrishna, Department of Pathology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Thomas Alex KodiatteDeepak Kalyansingh Burad, Thomas Alex Kodiatte, Banumathi Ramakrishna, Department of Pathology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Sayd Mohamed RajeebDeepak Kalyansingh Burad, Thomas Alex Kodiatte, Banumathi Ramakrishna, Department of Pathology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Ashish GoelDeepak Kalyansingh Burad, Thomas Alex Kodiatte, Banumathi Ramakrishna, Department of Pathology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Chundamannil Eapen EapenDeepak Kalyansingh Burad, Thomas Alex Kodiatte, Banumathi Ramakrishna, Department of Pathology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Banumathi RamakrishnaDeepak Kalyansingh Burad, Thomas Alex Kodiatte, Banumathi Ramakrishna, Department of Pathology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Christian Medical College · INChristian Medical College & Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the clinicopathological characteristics of neuroendocrine neoplasms (NEN) on liver samples and apply World Health Organization (WHO) 2010 grading of gastroenteropancreatic (GEP) NEN.

methodsClinicopathological features of 79 cases of NEN of the liver diagnosed between January 2011 to December 2015 were analyzed. WHO 2010 classification of GEP NEN was applied and the tumors were graded as G1, G2 or G3. Two more categories, D1/2 (discordant 1/2) and D2/3 (discordant 2/3) were also applied. The D1/2 grade tumors had a mitotic count of G1 and Ki-67 index of G2. The D2/3 tumors had a mitotic count of G2 and Ki-67 index of G3. The follow up details which were available till the end of the study period (December 2015) were collected.

resultsOf the 79 tumors, 16 each were G1 and G2, and 18 were G3 tumors. Of the remaining 29 tumors, 13 were assigned to D1/2 and 16 were D2/3 grade. Male preponderance was noted in all tumors except for G2 neoplasms, which showed a slight female predilection. The median age at presentation was 47 years (range 10-82 years). The most common presentation was abdominal pain (81%). Pancreas (49%) was the most common site of primary followed by gastrointestinal tract (24.4%) and lungs (18%). Radiologically, 87% of the patients had multiple liver lesions. Histopathologically, necrosis was seen in only D2/3 and G3 tumors. Microvascular invasion was seen in all grades. Metastasis occurred in all grades of primary NEN and the grades of the metastatic tumors and their corresponding primary tumors were similar in 67% of the cases. Of the 79 patients, 36 had at least one follow up visit with a median duration of follow up of 8.5 mo (range: 1-50 mo). This study did not show any impact of the grade of tumor on the short term clinical outcome of these patients.

conclusionLiver biopsy is an important tool for clinicopathological characterization and grading of NEN, especially when the primary is not identified. Eighty-seven percent of the patients had multifocal liver lesions irrespective of the WHO grade, indicating a higher stage of disease at presentation. Follow up duration was inadequate to derive any meaningful conclusion on long term outcome in our study patients.

Indexed as

AdolescentAdultAgedAged, 80 and overChildFemaleHumansImmunohistochemistryLiverLiver NeoplasmsMaleMiddle AgedNeuroendocrine TumorsRadiographyRetrospective StudiesYoung AdultGastroenteropancreatic neuroendocrine neoplasmsKi-67LiverMetastasisMicrovascular invasionNeuroendocrine neoplasms

Identifiers

PMID27833387
PMCPMC5083801
OpenAlexW2543980743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.